AR120626A1 - SALTS OF AN FGFR INHIBITOR - Google Patents
SALTS OF AN FGFR INHIBITORInfo
- Publication number
- AR120626A1 AR120626A1 ARP190101178A ARP190101178A AR120626A1 AR 120626 A1 AR120626 A1 AR 120626A1 AR P190101178 A ARP190101178 A AR P190101178A AR P190101178 A ARP190101178 A AR P190101178A AR 120626 A1 AR120626 A1 AR 120626A1
- Authority
- AR
- Argentina
- Prior art keywords
- salts
- fgfr
- fgfr inhibitor
- pyrido
- morpholin
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente hace referencia a formas de sal del inhibidor de receptores del factor de crecimiento de fibroblastos (FGFR) 3-(2,6-difluoro-3,5-dimetoxifenil)-1-etil-8-(morfolin-4-ilmetil)-1,3,4,7-tetrahidro-2H-pirrolo[3,2:5,6]pirido[4,3-d]pirimidin-2-ona, lo que incluye métodos para su preparación donde el compuesto es útil en el tratamiento de enfermedades mediadas por FGFR, tales como el cáncer. Reivindicación 1: Una sal que es una sal de ácido de 3-(2,6-difluoro-3,5-dimetoxifenil)-1-etil-8-(morfolin-4-ilmetil)-1,3,4,7-tetrahidro-2H-pirrolo[3,2:5,6]pirido[4,3-d]pirimidin-2-ona, que tiene la estructura de fórmula (1), o un hidrato o solvato de esta.This refers to salt forms of the fibroblast growth factor receptor (FGFR) inhibitor 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl) -1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one, including methods for its preparation where the compound is useful in the treatment of FGFR-mediated diseases, such as cancer. Claim 1: A salt which is a 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7- tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one, having the structure of formula (1), or a hydrate or solvate thereof.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862677040P | 2018-05-04 | 2018-05-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR120626A1 true AR120626A1 (en) | 2022-03-02 |
Family
ID=80996975
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP190101178A AR120626A1 (en) | 2018-05-04 | 2019-05-03 | SALTS OF AN FGFR INHIBITOR |
Country Status (1)
Country | Link |
---|---|
AR (1) | AR120626A1 (en) |
-
2019
- 2019-05-03 AR ARP190101178A patent/AR120626A1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP20078230A (en) | SALTS FROM A FGFR INHIBITOR | |
DOP2019000168A (en) | AMINO-TRIAZOLOPIRIDINE COMPOUNDS AND THEIR USE IN CANCER TREATMENT | |
BR112022012585A2 (en) | EGFR MUTANT FORMS INHIBITORS | |
CO2018003969A2 (en) | Imidazo [4,5-c] quinolin-2-one compounds | |
DOP2016000281A (en) | IMIDAZO COMPOUNDS [4,5-C] QUINOLIN-2-ONA AND ITS USE TO TREAT CANCER | |
CO2020015226A2 (en) | Solid forms of a fgfr inhibitor and processes to prepare them | |
DOP2018000065A (en) | DERIVATIVES OF 8- [6- [3- (AMINO) PROPOXI] -3-PIRIDIL] 1-ISOPROPILIMIDAZO [4,5-C] QUINOLIN-2-ONA AS SELECTED MODULATORS OF THE MUTED TELANGIECTASIA ATAXIA KINASE (ATM) FOR THE CANCER TREATMENT | |
DOP2018000115A (en) | IMIDAZO COMPOUNDS [4,5-C] QUINOLIN-2-ONA AND ITS USE IN CANCER TREATMENT | |
NI202000099A (en) | PURINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | |
AR108461A1 (en) | IMIDAZO COMPOUNDS [4,5-C] QUINOLIN-2-ONA AND ITS USE IN CANCER TREATMENT | |
DOP2016000308A (en) | COMPOUNDS OF 1, 3, 4-TIADIAZOL AND USE OF THE SAME FOR THE TREATMENT OF CANCER | |
NI201900094A (en) | DEUTERATED IMIDAZO [4, 5-c] QUINOLIN-2-ONA TYPE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | |
BR112019004236A2 (en) | compounds to treat diseases associated with mitochondrial dysfunction | |
CO2018010951A2 (en) | Cinnolin-4-amine compounds and their use in cancer treatment | |
CO2017011969A2 (en) | Imidazo [1,2-b] [1,2,4] triazine derivatives as antiparasitic agents | |
AR120626A1 (en) | SALTS OF AN FGFR INHIBITOR | |
CL2022002473A1 (en) | Salts of an fgfr inhibitor (divisional of 202002848). | |
CL2022002037A1 (en) | Use of an fgfr inhibitor compound; amorphous solid form; process for preparing the compound (div. sol. n° 202002839). |